Literature DB >> 19322116

Cortisol levels during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.

Nancy Fugate Woods1, Ellen Sullivan Mitchell, Kathleen Smith-Dijulio.   

Abstract

OBJECTIVE: Cortisol levels rise among some women during the late stage of the menopausal transition (MT), but we know little about changes in cortisol levels in relation to menopause-related factors (MT stage, urinary estrone glucuronide [E1G], testosterone, follicle-stimulating hormone [FSH]), stress-related factors (epinephrine, norepinephrine, and perceived stress), symptoms (hot flashes, mood, memory, and sleep), social factors (income adequacy, role burden, social support, employment, parenting, and history of sexual abuse), and health-related factors (depressed mood, perceived health, physical appraisal, body mass index, and smoking). The aim of the study was to examine the influence of menopause-related factors, stress-related factors, symptoms, social factors, and health-related factors on cortisol levels during the MT.
METHODS: Participants were a subset of Seattle Midlife Women's Health Study who provided data during the late reproductive, early and late MT stages, or early postmenopause and who were not using hormone therapy or corticosteroids (N = 132 women, up to 5,218 observations). Data provided included menstrual calendars for staging the MT, annual health reports, health diaries, and overnight urine specimens (assayed for cortisol, catecholamines, E1G, and FSH) between 1990 and 2005 were included. Perceived stress, symptoms, and health behaviors were assessed in a health diary. Health-related and social factors were assessed in an annual health update. Multilevel modeling was used to test the effects of menopause-related and other factors on overnight cortisol levels.
RESULTS: When tested with age as a measure of time, menopause-related covariates, including E1G, FSH, and testosterone, were associated with significant increases in overnight cortisol levels (P < 0.0001). Likewise, epinephrine and norepinephrine were each associated significantly with overnight cortisol levels (P < 0.0001). In multivariate analyses, E1G, FSH, and testosterone constituted the best set of predictors.
CONCLUSIONS: Overnight cortisol levels during the MT were associated with E1G, testosterone, and FSH levels. In addition, they were significantly and positively associated with epinephrine and norepinephrine. MT stage, symptoms, and social, stress-related, and health-related factors had little relationship to overnight cortisol levels when other biological indicators were considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322116      PMCID: PMC2749064          DOI: 10.1097/gme.0b013e318198d6b2

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  48 in total

1.  Changes in LDL density across the menopausal transition.

Authors:  M C Carr; K H Kim; A Zambon; E S Mitchell; N F Woods; C P Casazza; J Q Purnell; J E Hokanson; J D Brunzell; R S Schwartz
Journal:  J Investig Med       Date:  2000-07       Impact factor: 2.895

2.  Executive summary: Stages of Reproductive Aging Workshop (STRAW).

Authors:  M R Soules; S Sherman; E Parrott; R Rebar; N Santoro; W Utian; N Woods
Journal:  Fertil Steril       Date:  2001-11       Impact factor: 7.329

3.  The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity.

Authors:  Bill L Lasley; Nanette Santoro; John F Randolf; Ellen B Gold; Sybil Crawford; Gerson Weiss; Daniel S McConnell; Mary Fran Sowers
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

4.  Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: the Rancho Bernardo Study.

Authors:  G A Laughlin; E Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

5.  Ovarian function in late reproductive years in relation to lifetime experiences of abuse.

Authors:  J E Allsworth; S Zierler; N Krieger; B L Harlow
Journal:  Epidemiology       Date:  2001-11       Impact factor: 4.822

6.  Higher basal cortisol predicts verbal memory loss in postmenopausal women: Rancho Bernardo Study.

Authors:  G A Greendale; D Kritz-Silverstein; T Seeman; E Barrett-Connor
Journal:  J Am Geriatr Soc       Date:  2000-12       Impact factor: 5.562

7.  Physiologic markers of chronic stress in premenopausal, middle-aged women.

Authors:  Lynda H Powell; William R Lovallo; Karen A Matthews; Peter Meyer; A Rees Midgley; Andrew Baum; Arthur A Stone; Lynn Underwood; Judith J McCann; Kristi Janikula Herro; Marcia G Ory
Journal:  Psychosom Med       Date:  2002 May-Jun       Impact factor: 4.312

8.  Urinary free cortisol and sleep under baseline and stressed conditions in healthy senior women: effects of estrogen replacement therapy.

Authors:  P Prinz; S Bailey; K Moe; C Wilkinson; J Scanlan
Journal:  J Sleep Res       Date:  2001-03       Impact factor: 3.981

9.  Stress exposure, psychological distress, and physiological stress activation in midlife women with insomnia.

Authors:  Joan L F Shaver; Sandra K Johnston; Martha J Lentz; Carol A Landis
Journal:  Psychosom Med       Date:  2002 Sep-Oct       Impact factor: 4.312

10.  Is the menopausal transition stressful? Observations of perceived stress from the Seattle Midlife Women's Health Study.

Authors:  Nancy Fugate Woods; Ellen Sullivan Mitchell; Don B Percival; Kathleen Smith-DiJulio
Journal:  Menopause       Date:  2009 Jan-Feb       Impact factor: 2.953

View more
  22 in total

Review 1.  Perimenopause and cognition.

Authors:  Gail A Greendale; Carol A Derby; Pauline M Maki
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

2.  Hot flashes and midlife symptoms in relation to levels of salivary cortisol.

Authors:  Linda M Gerber; Lynnette L Sievert; Joseph E Schwartz
Journal:  Maturitas       Date:  2016-11-03       Impact factor: 4.342

3.  Vasomotor symptoms and lipid profiles in women transitioning through menopause.

Authors:  Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Ellen B Gold; Barbara Sternfeld; Hadine Joffe; Faith Selzer; Karen A Matthews
Journal:  Obstet Gynecol       Date:  2012-04       Impact factor: 7.661

Review 4.  Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation.

Authors:  Rebecca C Thurston; Hadine Joffe
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

Review 5.  The reproductive endocrinology of the menopausal transition.

Authors:  Laura Butler; Nanette Santoro
Journal:  Steroids       Date:  2011-03-16       Impact factor: 2.668

6.  Endocrine biomarkers and symptom clusters during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Nancy Fugate Woods; Lori Cray; Ellen Sullivan Mitchell; Jerald R Herting
Journal:  Menopause       Date:  2014-06       Impact factor: 2.953

Review 7.  Puberty and perimenopause: reproductive transitions and their implications for women's health.

Authors:  Lindsay Till Hoyt; April M Falconi
Journal:  Soc Sci Med       Date:  2015-03-14       Impact factor: 4.634

8.  Glucocorticoid receptor antagonist and siRNA prevent senescence of human bone marrow mesenchymal stromal cells in vitro.

Authors:  Na Wei; Yang Yu; Vijaya Joshi; Thomas Schmidt; Fang Qian; Aliasger K Salem; Clark Stanford; Liu Hong
Journal:  Cell Tissue Res       Date:  2013-08-21       Impact factor: 5.249

9.  Constipation and diarrhea during the menopause transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.

Authors:  Nini G L Callan; Ellen S Mitchell; Margaret M Heitkemper; Nancy F Woods
Journal:  Menopause       Date:  2018-06       Impact factor: 2.953

10.  The association between abuse history in childhood and salivary rhythms of cortisol and DHEA in postmenopausal women.

Authors:  Olivia R Orta; Tianyi Huang; Laura D Kubzansky; Kathryn L Terry; Brent A Coull; Michelle A Williams; Shelley S Tworoger
Journal:  Psychoneuroendocrinology       Date:  2019-11-14       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.